Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission
Latest Information Update: 01 Aug 2022
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Malaria
- Focus Adverse reactions; Pharmacokinetics
- Acronyms ECG-Lihir
- 06 Jul 2022 Results published in the Antimicrobial Agents and Chemotherapy
- 02 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 19 Nov 2015 New trial record